How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Biopsy Instrumens Market
- By Product Type: Core Needle Biopsy Devices, Fine Needle Aspiration Devices, Surgical Biopsy Instruments, Vacuum-Assisted Biopsy Systems, Endoscopic Biopsy Forceps
- By Application: Breast Biopsy, Lung Biopsy, Prostate Biopsy, Gastrointestinal Biopsy, Skin Biopsy
- By Technology: Vacuum-Assisted Biopsy, Automated Biopsy Devices, Manual Biopsy Devices, Imaging-Guided Biopsy Systems
- By End User: Hospitals, Diagnostic Laboratories, Ambulatory Surgical Centers, Specialty Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Core Needle Biopsy Devices leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Biopsy Instrumens Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Application 5
Technology 4
End User 4
Companies profiled
Medtronic plc
Becton
Dickinson and Company (BD)
Hologic Inc.
Cook Medical LLC
Stryker Corporation
Olympus Corporation
Boston Scientific Corporation
C.R. Bard
Inc. (now part of BD)
Argon Medical Devices Inc.
Merit Medical Systems Inc.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cook Medical LLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Stryker Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Olympus Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Boston Scientific Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →C.R. Bard
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Inc. (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Argon Medical Devices Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Merit Medical Systems Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →CONMED Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Teleflex Incorporated
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Smith & Nephew plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Baxter International Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Integra LifeSciences Holdings Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →
Global · 2025–2033
$10,073M by 2033 · 11.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Core Needle Biopsy Devices58.8
- Fine Needle Aspiration Devices17.0
- Surgical Biopsy Instruments6.4
- Vacuum-Assisted Biopsy Systems8.1
- Endoscopic Biopsy Forceps9.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,442M → $3,091M · 10.0%
Europe$1,005M → $2,321M · 11.0%
Asia Pacific$917.6M → $2,182M · 11.4%
Latin America$568.1M → $1,343M · 11.4%
Middle East and Africa$437.0M → $974.7M · 10.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.952026
10.962027
10.982028
11.002029
11.002030
11.022031
11.032032
11.042033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic plc8.9
- Becton15.2
- Dickinson and Company (BD)11.8
- Hologic Inc.13.2
- Cook Medical LLC9.9
- Stryker Corporation12.9
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type30.1%
Application28.9%
Technology11.8%
End User29.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.2
- Europe23.4
- Asia Pacific22.0
- Latin America13.6
- Middle East and Africa9.8
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 85 | 87 | 91 | 83 | 95 | 95 | 89 |
| Becton | 82 | 87 | 77 | 88 | 70 | 92 | 83 |
| Dickinson and Company (BD) | 75 | 64 | 66 | 75 | 75 | 71 | 71 |
| Hologic Inc. | 63 | 57 | 62 | 70 | 70 | 59 | 64 |
| Cook Medical LLC | 63 | 62 | 73 | 58 | 67 | 55 | 63 |
| Stryker Corporation | 67 | 67 | 68 | 58 | 50 | 51 | 60 |
| Olympus Corporation | 63 | 46 | 47 | 55 | 62 | 63 | 56 |
| Boston Scientific Corporation | 38 | 60 | 60 | 60 | 48 | 41 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic plc
- Becton
- Dickinson and Company (BD)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic plc | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Becton | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Dickinson and Company (BD) | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Hologic Inc. | − | − | ◐ | ◐ | ✓ | − |
| Cook Medical LLC | ◐ | ◐ | ◐ | − | − | ◐ |
| Stryker Corporation | ◐ | ✓ | − | − | − | ◐ |
| Olympus Corporation | ◐ | − | − | − | ◐ | ◐ |
| Boston Scientific Corporation | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic plc89
2Becton83
3Dickinson and Company (BD)71
4Hologic Inc.64
5Cook Medical LLC63
6Stryker Corporation60
7Olympus Corporation56
8Boston Scientific Corporation51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Medtronic plcBecton
Challenger1
Strong scale, closing on the leaders.
Dickinson and Company (BD)
Contender3
Focused players with pockets of strength.
Hologic Inc.Cook Medical LLCStryker Corporation
Niche2
Specialists in a single segment or region.
Olympus CorporationBoston Scientific Corporation
Go-to-market strategy
Land Product Type in North America, then scale across Biopsy Instrumens Market — a $899M beachhead inside a $13.0B market.
Beachhead (SOM)$899Mobtainable near-term
Serviceable (SAM)$5.12Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Core Needle Biopsy Devices
Best fit — highest urgency & budget in Product Type.
Economic buyer81 fit
Fine Needle Aspiration Devices
Strong fit — clear ROI and a fast path to value.
End user66 fit
Surgical Biopsy Instruments
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve19%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biopsy Instrumens Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified21%
Evaluation15%
Closed-won7%
$13.3KCAC
$49KLTV
3.6:1LTV : CAC
< 3 moCAC payback
Investment thesis
Biopsy Instrumens Market is a high-growth opportunity — $8.54B by 2033, compounding at 10.3%.
TAM · 2025$3.91Btoday
TAM · 2033$8.54Bforecast
CAGR10.3%2027–2033
Cumulative$53.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.54BTotal addressable market
SAM$3.04BServiceable available market
SOM$552MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.3% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.54BLarge & growingTAM by 2033 at 10.3% CAGR
$3.04BServiceable nowreachable with today’s model
$552MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.66BBear6.7% CAGR
$8.54BBase10.3% CAGR
$10.9BBull13.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Biopsy Instrumens Market — a $5.53B market by 2033. Plan: grow share from 7.5% to 14.1%.
Market size · 2033$5.53Btotal addressable
Market CAGR7.7%2027–2033
Target share14.1%from 7.5% today
Revenue ambition$779Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.5% | 14.1% | Ahead |
| Revenue | $453M | $779M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 32.2% | 39.9% | On track |
| Customer retention | 91.5% | 95.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $99M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Sales deck · value proposition
Win the Biopsy Instrumens Market conversation — a $4.57B market you can size, segment and defend in minutes.
Market size · 2033$4.57Btotal opportunity
Growth6.9%CAGR to 2033
Addressable buyers1,578+accounts in scope
Typical ROI6.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.8×return on cost, year one
< 3 mopayback period
$83K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Medtronic plcBectonDickinson and Company (BD)Hologic Inc.Cook Medical LLCStryker CorporationOlympus CorporationBoston Scientific Corporation+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biopsy Instrumens Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biopsy Instrumens Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Biopsy Needle Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportBiopsy Punches Market
Market size, share, segmentation and regional forecast.
$327M market · 2025 base year
View reportBio-Rad Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBioreactors & Fermenters Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportBioremediation Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportBioresorbable (Resorbable) Polymers Market
Market size, share, segmentation and regional forecast.
$461M market · 2025 base year
View reportBio-Resorbable Ceramic Market
Market size, share, segmentation and regional forecast.
$407M market · 2025 base year
View reportBio-Resorbable Pins and Screw Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportBioresorbable Polymer Market
Market size, share, segmentation and regional forecast.
$942M market · 2025 base year
View reportBIOS Firmware Technology Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBio-Safe Hand-Washing Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportBiosafety Testing Services for Biologics BPO Service Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.